Bb Biotech Ag Acquired Stake in Halozyme Therapeutics Inc

February 15, 2018 - By Michael Collier

 Bb Biotech Ag Acquired Stake in Halozyme Therapeutics Inc

Investors sentiment decreased to 1.26 in 2017 Q3. Its down 0.76, from 2.02 in 2017Q2. It fall, as 14 investors sold Halozyme Therapeutics, Inc. shares while 44 reduced holdings. 18 funds opened positions while 55 raised stakes. 118.53 million shares or 0.58% less from 119.22 million shares in 2017Q2 were reported.

Moreover, Panagora Asset Mgmt Inc has 0.06% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 856,579 shares. Teacher Retirement System Of Texas has 10,375 shares. Cornerstone Management Ltd Limited Liability Company accumulated 58,363 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Moreover, Voya Inv Mgmt Ltd Co has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Dupont Capital Mngmt Corp, a Delaware-based fund reported 48,270 shares. Fisher Asset Mgmt has 583,221 shares. 203,595 were reported by Chicago Equity Prtnrs Lc. Manufacturers Life Ins Co The reported 0.02% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Rhumbline Advisers has 143,342 shares for 0.01% of their portfolio. The Minnesota-based Sit Investment Associates has invested 0.03% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). The Australia-based Macquarie Group Incorporated Limited has invested 0.02% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Principal Fincl Gru invested in 16,941 shares. Jane Street Group Limited Liability accumulated 0% or 23,447 shares. Atlantic Tru Group Ltd Llc accumulated 25,718 shares or 0% of the stock.

The New Bb Biotech Ag Holding in Halozyme Therapeutics Inc

Bb Biotech Ag reported SC 13G/A form with the SEC for Halozyme Therapeutics Inc. Access it here: 000119312518045492. As reported by Bb Biotech Ag, the filler owns 6% or 8,520,137 shares of the Health Care–company.

Halozyme Therapeutics Inc stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Bb Biotech Ag’s positive view for Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc Institutional Sentiment

Filings show 167 investors own Halozyme Therapeutics Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 8810321. 105199434 were owned by these investors. 32 funds opened new Halozyme Therapeutics Inc stakes, 62 increased positions. There were 17 that closed positions and 49 reduced them.

2 investors had the stock in their top 10. Some are: Senzar Asset Management Llc, Third Security Llc, Msd Partners L.P., Bb Biotech Ag..

Third Security Llc is an investor bullish on Halozyme Therapeutics Inc, owning 19829337 shares as of Q3 2015 for 10.59% of its portfolio. Leisure Capital Management owns 24605 shares or 0.36% of its portfolio. CA First Republic Investment Management Inc have 0.01% of its portfolio for 43000 shares. Further, Franklin Street Advisors Inc reported stake worth 0.08% of its portfolio. The CA Doheny Asset Management owns 51415 shares. Halozyme Therapeutics Inc is 0.36% of its portfolio.

Business Profile

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

SEC Form 13G.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on February, 27. They expect $0.67 earnings per share, up 419.05 % or $0.88 from last year’s $-0.21 per share. HALO’s profit will be $94.51M for 6.97 P/E if the $0.67 EPS becomes a reality. After $0.02 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3,250.00 % EPS growth.

The stock increased 1.47% or $0.27 during the last trading session, reaching $18.68. About 331,646 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since February 15, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.64 billion. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It currently has negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 9 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Halozyme Therapeutics has $27 highest and $12 lowest target. $20.43’s average target is 9.37% above currents $18.68 stock price. Halozyme Therapeutics had 21 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Barclays Capital given on Tuesday, September 22. As per Friday, December 4, the company rating was initiated by Wells Fargo. As per Wednesday, July 26, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by Citigroup on Wednesday, November 18. Piper Jaffray maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Thursday, September 14. Piper Jaffray has “Buy” rating and $26.0 target. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Market Outperform” rating by JMP Securities on Tuesday, August 11. Citigroup downgraded the stock to “Neutral” rating in Friday, January 6 report. The stock has “Market Perform” rating by BMO Capital Markets on Wednesday, November 8. JMP Securities maintained the stock with “Market Outperform” rating in Wednesday, March 9 report. Piper Jaffray maintained it with “Buy” rating and $2000 target in Wednesday, August 9 report.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: which released: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme …” on January 19, 2018, also with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on January 17, 2018, published: “Halozyme Therapeutics: ENHANZE Alone Is Well Worth A Huge Bet On This …” on January 22, 2018. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: and their article: “Why Halozyme Went Down Yesterday?” published on January 17, 2018 as well as‘s news article titled: “Timpani Capital Management LLC Buys Mimecast, Alkermes PLC, Halozyme …” with publication date: February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: